ISBER 2017 travel grant winner: Brad Godfrey
As a global biobanking organisation, ISBER creates opportunities for networking, education, and brings together innovative approaches to evolving challenges in biological and environmental repositories. However, it’s also known as the ‘the place to be’ in the biobanking calendar and this year’s conference theme is ‘Due North: Aligning Biobanking Practice with Evolving Evidence and Innovation’. To support such an exciting event, we recently ran an ISBER 2017 travel grant competition and are excited to be able to share our interview with winner Brad Godfrey from Michigan Medicine at the University of Michigan, USA.
Brad, please tell us about your role and your research:
“I am the Lab Manager for several chronic kidney disease studies at the Applied Systems Biology Core at Michigan Medicine. I receive clinical biospecimen shipments from various sites around the world and I will catalog and store them. Part of my role is processing the tissues to ultimately perform transciptomics profiling on the compartments of the kidney and whole genome sequencing on the blood. I also provide blood and urine samples to our ancillary studies to perform other types of molecular characterization.”
“I work entirely with human patient samples. We take a complete -omics approach to kidney disease starting with protocol biopsies and correlating tissue transcriptomics data with longitudinal samples or urine and blood. We have a collection of over 250,000 urine and blood samples across several chronic kidney disease cohorts, collected from patients for over a decade, that we use ourselves or ship to ancillary studies throughout the world. Our interdisciplinary research team integrates information from a wide spectrum of human cohort studies we have initiated or are intimately involved with. In these prospective cohort studies, we test the precision medicine concept for renal disease by integrating information along the genotype-phenotype continuum using carefully monitored environmental exposures, genetic predispositions, epigenetic markers, transcriptional networks, proteomic profiles, metabolic fingerprints, digital histological biopsy archive, and prospective clinical disease characterization.”
What do you hope to learn/gain from attending the conference?
“I have several goals for attending ISBER. First, learn any regulatory changes that have recently occurred. We deal with human tissue exclusively and need to be aware of the latest regulations. I will get updated on the latest trends in biobanking and what our outside studies will expect when requesting samples. Knowing the most effective approaches will help further the biobanking effort. We collect various biosamples from low and moderate areas of the world. I will be better able to communicate with our clinical coordinators how to properly obtained, preserve, store, and ship these samples under less-than-ideal circumstances. This is crucial in our goals to study kidney disease such as HIV-induced nephropathy that disproportionately affects less advantaged areas.”
Again our congratulations go out to Brad and we look forward to hearing about his experience and key findings from the ISBER 2017 conference!
Going to ISBER 2017?
Come and meet our team at booth #30!
Find out more here